Rossari Biotech Ltd

Rossari Biotech Limited has announced the closure of its trading window for designated persons and their immediate relatives, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut from October 01, 2026, until 48 hours after the announcement of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. The specific date for the Board Meeting to approve these results will be communicated later.

Rossari Biotech Ltd has informed the exchange that it will not be participating in the "One-on-One & Group, Nirmal Bang's Semi-Annual Investor Conference" scheduled for Monday, August 10, 2026. This follows a previous intimation letter dated August 03, 2026. The company requests this non-participation be noted and disseminated.

Rossari Biotech Ltd has issued a clarification regarding the number of stock options granted under its Employee Stock Option Plan 2019. Previously stated as 4000 options in a letter dated July 18, 2026, the company has corrected this to 5000 options. This correction applies to the total number of options granted by the Board, including those detailed in Annexure I of the original communication. All other details from the previous letter remain unchanged. This is a clarification of a previously announced ESOP grant.

Rossari Biotech announced its financial results for the quarter ended June 30, 2026. Consolidated revenue from operations grew 28% year-on-year to ₹697.2 crore, reaching its highest-ever quarterly revenue. EBITDA improved by 19% to ₹80.6 crore, though the EBITDA margin slightly decreased to 11.6% from 12.5%. Profit After Tax (PAT) saw a 4% increase to ₹35.1 crore. Standalone revenue also surged by 32% to ₹482.3 crore. The company highlighted strong momentum in domestic and international businesses, driven by its HPPC, TSC, and AHN segments. Key developments include establishing a new greenfield blending facility in Thailand to serve Southeast Asia and completing the sale of its Andheri office as part of non-core asset monetization.

Rossari Biotech Ltd's Board of Directors convened on July 18, 2026, approving the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026. The Board also approved the grant of 4000 stock options under the Rossari Employee Stock Option Plan - 2019 (ESOP 2019) and the allotment of 2500 equity shares pursuant to the exercise of options under the same plan. Additionally, the company approved the transfer of its 100% shareholding in Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. as part of an internal group restructuring. The financial results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors.

Rossari Biotech Ltd announced the grant of 4000 stock options under its Employee Stock Option Plan - 2019 (ESOP 2019) during a Board of Directors meeting held on July 18, 2026. The Board also approved the unaudited financial results for the quarter ended June 30, 2026, and the allotment of 2500 equity shares upon exercise of options. Additionally, the company approved the transfer of its 100% shareholding in Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. as part of an internal restructuring.

Rossari Biotech Ltd announced its unaudited financial results for the quarter ended June 30, 2026, both standalone and consolidated. The Board of Directors approved these results following a review by the Audit Committee. The company also approved the grant of 4000 stock options under its ESOP 2019 plan and the allotment of 2500 equity shares under the same plan. Additionally, the Board approved the transfer of 100% shareholding in Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. as part of an internal group restructuring. The statutory auditors have conducted a limited review of the financial results.

Rossari Biotech Ltd's Board of Directors convened on July 18, 2026, approving the unaudited financial results for the quarter ended June 30, 2026 (Standalone and Consolidated). The Board also approved the grant of 4000 stock options under the ESOP 2019 plan and the allotment of 2500 equity shares upon exercise of options. Additionally, the company approved the transfer of its 100% shareholding in Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. as part of an internal group restructuring. The results were subjected to a limited review by statutory auditors.

Rossari Biotech Ltd has announced that its Board of Directors will convene on July 18, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026, on both standalone and consolidated bases. Concurrently, the company has confirmed that the trading window for its securities will remain closed for designated persons and their immediate relatives from July 1, 2026, until 48 hours after the announcement of these financial results. The company's website will host this intimation.

Rossari Biotech Ltd has announced its 17th Annual General Meeting (AGM) will be held on Monday, July 20, 2026, at 11:00 AM IST. The meeting will be conducted entirely through Video Conferencing/Other Audio Visual Means (VC/OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the Financial Year 2025-26, declaration of a dividend of ₹0.50 per equity share, appointment of Mr. Edward Menezes as a director, and approval for material related party transactions with Unitop Chemicals Private Limited. The notice of the AGM is available on the company's website and forms part of the Integrated Annual Report for FY 2025-26.